5 completed, 3 unknown, 2 active not recruiting, 1 recruiting. 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 5, Unknown 3, Active not recruiting 2, Recruiting 1, Terminated 1 |
Follow Multi-centric Castleman's Disease: new trials by email Literature Review of Multi-centric Castleman's Disease trials Research Report on Multi-centric Castleman's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease Daratumumab SC - Lymphoma, Primary Effusion | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2024-07-10 | 2026-10-16 |
| Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi Rituximab, Etoposide - Multicentric Castleman Disease | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 15 | 2021-06-22 | 2026-07-30 |
| Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease Siltuximab - Idiopathic Multicentric Castleman's Disease | Phase 2 | Terminated | RECORDATI GROUP | 22 | 2021-03-31 | 2021-04-19 |
| Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial Zanubrutinib - Idiopathic Multicentric Castleman's Disease | Phase 2 | Unknown | Peking Union Medical College Hospital | 30 | 2021-01-01 | 2021-02-09 |
| Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease Sirolimus - Castleman Disease, Castleman's Disease, Multicentric | Phase 2 | Active not recruiting | University of Pennsylvania | 7 | 2019-09-25 | 2026-08-20 |
| BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) Bortezomib, Cyclophosphamide, Dexamethason - Idiopathic Multicentric Castleman's Disease | Phase 2 | Unknown | Peking Union Medical College Hospital | 30 | 2019-01-01 | 2019-06-12 |
| TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Thalidomide, cyclophosphamide and prednisone - Multicentric Castleman Disease | Phase 2 | Unknown | Peking Union Medical College Hospital | 25 | 2017-01-01 | 2020-04-16 |
| Tocilizumab for KSHV-Associated Multicentric Castleman Disease Zidovudine, Tocilizumab, Valganciclovir (VGC) - Castleman Disease, Multicentric Castleman Disease | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2011-09-13 | 2020-10-27 |
| A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Siltuximab - Multicentric Castleman's Disease | Phase 2 | Completed | Janssen Research & Development, LLC | 60 | 2011-04-01 | 2018-05-22 |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Siltuximab, Placebo, Best Supportive Care (BSC) - Multicentric Castleman's Disease | Phase 2 | Completed | Janssen Research & Development, LLC | 79 | 2010-03-18 | 2018-03-21 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis tanespimycin - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 37 | 2006-05-01 | 2012-03-15 |
| Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Etoposide, Interferon-alpha, Rituximab - Lymphoproliferative Disorder, HHV-8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 75 | 2004-10-28 | 2026-10-29 |
Macular dystrophy, corneal type 1 (4) · Castleman Disease (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms (2) · Sarcoma, Kaposi (2) · Acquired Immunodeficiency Syndrome (1) · Angiolymphoid Hyperplasia with Eosinophilia (1) · Burkitt Lymphoma (1) · HIV Infections (1) · Leukemia (1) · Leukemia, Hairy Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphadenopathy (1) · Lymphoma (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Infections (4) · Lymphoproliferative Disorders (4) · Virus Diseases (4) · DNA Virus Infections (3) · Herpesviridae Infections (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · Immunologic Deficiency Syndromes (2)
Cyclophosphamide (3) · siltuximab (3) · Bortezomib (2) · Etoposide (2) · Prednisone (2) · Rituximab (2) · Sirolimus (2) · Valganciclovir (2) · Zidovudine (2) · Doxorubicin (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Interferon-alpha (1) · Thalidomide (1) · Vincristine (1)
National Cancer Institute (NCI) (3) · Peking Union Medical College Hospital (3) · Janssen Research & Development, LLC (2) · National Institutes of Health Clinical Center (CC) (1) · RECORDATI GROUP (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Pennsylvania (1)
United States (8) · China (5) · Belgium (2) · Brazil (2) · Canada (2) · Egypt (2) · France (2) · Germany (2) · Hong Kong (2) · Israel (2) · New Zealand (2) · Norway (2) · Singapore (2) · South Korea (2) · Spain (2)
Robert Yarchoan, M.D. (3) · Antonio T. Fojo, MD, PhD (1) · Chris Keuker, MD (1) · Joshua Brandstadter, MD, PhD, MSc (1) · Yuri Fedoriw, MD (1)
PMID 21487108, PMID 24174627, PMID 25042199, PMID 25331113, PMID 28087540, PMID 30760451, PMID 31408438, PMID 32206779, PMID 32276276, PMID 33284946, PMID 33720337, PMID 35793409, PMID 36928290, PMID 38546960, PMID 38941593, PMID 41845569
2009 (1), K01TW011470 (1)